Head-to-head evidence
Gosogliptin vs Trelagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Gosogliptin
Developed by SatRx
NCT03088670 · Phase 3 · completed
The study used randomization and an active comparator, but it was open-label and its primary endpoint was change in HbA1c, a surrogate measure rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Trelagliptin · Zafatek
Developed by Takeda Pharmaceutical Company
NCT03940183 · Phase 3 · completed
The trial randomized 254 participants to trelagliptin or placebo and used quadruple blinding. Its primary endpoint was the surrogate measure of change in HbA1c at week 24, but results were not posted, so whether the comparison favored trelagliptin is unknown.
Next expected readout: December 2026 · NCT07073768 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gosogliptin's landscape · Trelagliptin's landscape